A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä

MYC PROTEIN - PARTNERS AND ANTAGONISTS




TekijätVASTRIK I, MAKELA TP, KOSKINEN PJ, KLEFSTROM J, ALITALO K

KustantajaBEGELL HOUSE INC

Julkaisuvuosi1994

JournalCritical Review in Oncogenesis

Tietokannassa oleva lehden nimiCRITICAL REVIEWS IN ONCOGENESIS

Lehden akronyymiCRIT REV ONCOGENESIS

Vuosikerta5

Numero1

Aloitussivu59

Lopetussivu68

Sivujen määrä10

ISSN0893-9675

DOIhttps://doi.org/10.1615/CritRevOncog.v5.i1.30


Tiivistelmä
One of the first oncogenes identified from human tumors was c-myc, which is frequently activated in Burkitt's lymphomas due to chromosomal translocations. Subsequently, members of the myc oncogene family were found to be amplified in neuroblastoma and small-cell lung cancer. In normal cells, Myc activity has been shown to be both necessary and sufficient for resting cells to enter the cell cycle. Interestingly, it appears that Myc not only drives the cell cycle, but also induces cell death by apoptosis in certain situations. Myc contains a transcriptional activation domain and a basic helix-loop-helix-leucine zipper DNA-binding and dimerization domain. As a heterodimer with a structurally related protein, Max, Myc can bind DNA in a sequence-specific manner. These results suggest that the Myc/Max heterodimer functions as a transcriptional activator of genes that are critical for the regulation of cell growth.



Last updated on 2024-26-11 at 21:56